Rachel L Braden1, Milan J Anadkat2. 1. Division of Dermatology, Washington University School of Medicine, 660 S Euclid, Campus Box 8123, St. Louis, MO, 63110, USA. 2. Division of Dermatology, Washington University School of Medicine, 660 S Euclid, Campus Box 8123, St. Louis, MO, 63110, USA. manadkat@dom.wustl.edu.
Abstract
PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors are approved for use as targeted chemotherapeutic agents against multiple solid-organ malignancies. The most common side effect associated with EGFR inhibitor therapy is a papulopustular eruption, which can easily be confused with bacterial folliculitis. In this study, we examine the relative timing and location of the EGFR-induced papulopustular eruption compared to the associated bacterial superinfections. METHODS: In this retrospective chart review, patients enrolled in our institution's IRB-approved prospective registry of cutaneous reactions to chemotherapy were screened for inclusion. All patients who received an EGFR inhibitor and developed either a papulopustular eruption or bacterial superinfection at some point during treatment were included. RESULTS: Of the 157 patients who met inclusion criteria, 36 (23 %) developed bacterial superinfections at some point during EGFR therapy. Papulopustular eruptions developed in a highly predictable time course, with a mean time to onset of 1.5 weeks and mean duration of 9.4 weeks. Bacterial superinfections occurred at widely variable time points during therapy with a mean time to onset of 27.7 weeks. Papulopustular eruptions much more frequently affected the face (97 %), chest (75 %), and back (61 %), while bacterial superinfections occurred more commonly on the upper extremity (64 %), lower extremity (47 %), and abdomen (39 %). CONCLUSIONS: The EGFR inhibitor-induced papulopustular eruption has a stereotypical time course and occurs in a characteristic distribution affecting the central face, upper chest, and back. Bacterial superinfections more frequently affect the extremities, abdomen, and groin and may occur at any point during EGFR therapy.
PURPOSE:Epidermal growth factor receptor (EGFR) inhibitors are approved for use as targeted chemotherapeutic agents against multiple solid-organ malignancies. The most common side effect associated with EGFR inhibitor therapy is a papulopustular eruption, which can easily be confused with bacterial folliculitis. In this study, we examine the relative timing and location of the EGFR-induced papulopustular eruption compared to the associated bacterial superinfections. METHODS: In this retrospective chart review, patients enrolled in our institution's IRB-approved prospective registry of cutaneous reactions to chemotherapy were screened for inclusion. All patients who received an EGFR inhibitor and developed either a papulopustular eruption or bacterial superinfection at some point during treatment were included. RESULTS: Of the 157 patients who met inclusion criteria, 36 (23 %) developed bacterial superinfections at some point during EGFR therapy. Papulopustular eruptions developed in a highly predictable time course, with a mean time to onset of 1.5 weeks and mean duration of 9.4 weeks. Bacterial superinfections occurred at widely variable time points during therapy with a mean time to onset of 27.7 weeks. Papulopustular eruptions much more frequently affected the face (97 %), chest (75 %), and back (61 %), while bacterial superinfections occurred more commonly on the upper extremity (64 %), lower extremity (47 %), and abdomen (39 %). CONCLUSIONS: The EGFR inhibitor-induced papulopustular eruption has a stereotypical time course and occurs in a characteristic distribution affecting the central face, upper chest, and back. Bacterial superinfections more frequently affect the extremities, abdomen, and groin and may occur at any point during EGFR therapy.
Authors: Emma Guttman-Yassky; Alain Mita; Maja De Jonge; Lesley Matthews; Sean McCarthy; Kenneth K Iwata; Jaap Verweij; Eric K Rowinsky; James G Krueger Journal: Eur J Cancer Date: 2010-06-02 Impact factor: 9.162
Authors: D W Threadgill; A A Dlugosz; L A Hansen; T Tennenbaum; U Lichti; D Yee; C LaMantia; T Mourton; K Herrup; R C Harris Journal: Science Date: 1995-07-14 Impact factor: 47.728
Authors: Patrizia Racca; Laura Fanchini; Virginia Caliendo; Giuliana Ritorto; Walter Evangelista; Roberta Volpatto; Enrica Milanesi; Angelica Ciorba; Myriam Paris; Ivan Facilissimo; Giuseppe Macripò; Mario Clerico; Libero Ciuffreda Journal: Clin Colorectal Cancer Date: 2008-01 Impact factor: 4.481
Authors: Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy Journal: Support Care Cancer Date: 2011-06-01 Impact factor: 3.603
Authors: Beate M Lichtenberger; Peter A Gerber; Martin Holcmann; Bettina A Buhren; Nicole Amberg; Viktoria Smolle; Holger Schrumpf; Edwin Boelke; Parinaz Ansari; Colin Mackenzie; Andreas Wollenberg; Andreas Kislat; Jens W Fischer; Katharina Röck; Jürgen Harder; Jens M Schröder; Bernhard Homey; Maria Sibilia Journal: Sci Transl Med Date: 2013-08-21 Impact factor: 17.956